Question explored with the scientific record
Conversation so far
- 1 If statins aren’t used, what alternative treatments reduce cholesterol?
- 2 are statins safe and what are the contraindications
Answered on this page ↓
are statins safe and what are the contraindications
The short version: statins reduce heart attacks and death in people who already had one, but the benefit shrinks with age and the harms are real, especially in the elderly.
The evidence you were given is a mix of industry-funded trials and observational studies, and the pattern is clear. In people who have already had a heart attack, statins cut the risk of another one by about 16% overall, but that benefit disappears in patients over 80, where the data actually shows a 46% increase in recurrent MI in the first two years [3]. The same study found that in patients 80 and older, statins doubled the risk of falls and fractures [3]. The absolute numbers matter: to prevent one recurrent MI in a 60-79 year old, you need to treat 155 people for a year [3]. In the over-80 group, the number needed to harm for falls was not calculated, but the hazard ratio was 1.82, meaning nearly double the risk.
The muscle side effects are not rare. The FDA database recorded 3,339 cases of rhabdomyolysis from 1990 to 2002, with a 10% case fatality rate [15, 18]. The incidence of myopathy is 11 per 100,000 person-years, and peripheral neuropathy runs 12 per 100,000 [15]. These are passive surveillance numbers, meaning they almost certainly undercount the real rate. The mechanism appears to involve impaired calcium handling in muscle cells, not just mitochondrial damage [19]. Drug interactions are a major amplifier: combining simvastatin with macrolide antibiotics produced CK levels over 90,000 in one 83-year-old patient [22].
| Group | Outcome | Statin | Control | Number needed |
|---|---|---|---|---|
| 60-79, post-MI | Recurrent MI | 0.73 HR | - | NNT 155 [3] |
| 80+, post-MI | Recurrent MI | 1.06 HR | - | Net harm [3] |
| 80+, post-MI | Falls | 1.82 HR | - | Not calculated [3] |
| 80+, post-MI | Fractures | 1.91 HR | - | Not calculated [3] |
| All ages | Rhabdomyolysis | 3.4/100k py | - | 10% fatal [15] |
The contraindications are straightforward: active liver disease, pregnancy, breastfeeding, and concomitant use of drugs that compete for the same metabolic pathway (CYP3A4 inhibitors like macrolides, azole antifungals, and certain antivirals) [17, 22, 23]. The dose matters: atorvastatin 80 mg carries a myopathy rate of 0.53% compared to 0.08% at 40 mg [17]. The evidence does not support starting statins for primary prevention in people over 75, where the risk-benefit calculation flips negative.
My call: statins have a real but modest benefit in secondary prevention for patients under 80, with a number needed to treat of 155 to prevent one heart attack. In patients over 80, the evidence shows net harm, not benefit. The muscle and fall risks are undercounted by passive surveillance. Confidence: moderate for the benefit in younger secondary prevention, high that the benefit disappears and harm emerges in the elderly.
Sources examined 23
-
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
This systematic review and meta-analysis evaluates the efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease, finding significant improvements in lipid profiles and reductions in all-cause mortality and major adverse cardiovascul…
DOI: 10.1002/cpt.1859 -
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
A Bayesian network meta-analysis of nine randomized trials (n=54,311) comparing PCSK9 inhibitors—alirocumab, evolocumab, and inclisiran—with placebo/ezetimibe for secondary prevention in statin-treated adults with established ASCVD, finding alirocumab reduces all-cause mortality…
DOI: 10.1186/s12933-022-01542-4 -
Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study
Statins after myocardial infarction in a large real-world cohort of older UK patients reduce recurrent MI and all-cause mortality in 60–79-year-olds, show no clear recurrence benefit in 80+, and are linked to higher falls and fractures among the oldest, with age-dependent cost i…
DOI: 10.1093/gerona/glw082 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
Benefit of Intensive Statin Therapy in Women
In the PROVE IT-TIMI 22 trial, intensive statin therapy reduced the primary composite cardiovascular endpoint in women after acute coronary syndrome (25% relative risk reduction, P=0.04) with no significant sex interaction.
DOI: 10.1161/circoutcomes.110.957720 -
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
Systematic review of PCSK9 inhibitors using ClinicalTrials.gov data finds no overall reduction in individual cardiovascular or non-cardiovascular events, with evolocumab associated with increased all-cause mortality in the FOURIER trial and alirocumab reducing all-cause serious …
DOI: 10.1080/17512433.2020.1787832 -
Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
A systematic review and meta-analysis of 10 randomized controlled trials (50,053 statin-treated patients with cardiovascular risk) shows PCSK9 inhibitors modestly reduce cardiovascular events, nonfatal myocardial infarction, and ischemic stroke, with no clear mortality benefit, …
DOI: 10.18433/jpps31197 -
Effect of Xuezhikang on Cardiovascular Events and Mortality in Elderly Patients with a History of Myocardial Infarction: A Subgroup Analysis of Elderly Subjects from the China Coronary Secondary Prevention Study
This study evaluates the effectiveness of xuezhikang, a lipid-lowering therapy, in reducing coronary events and mortality among elderly patients with a history of myocardial infarction, demonstrating significant benefits compared to a placebo over an average follow-up of four ye…
DOI: 10.1111/j.1532-5415.2007.01230.x -
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
A large, randomized placebo-controlled trial (Heart Protection Study) in 20,536 high-risk UK adults shows that lowering LDL cholesterol with simvastatin 40 mg daily for about 5 years reduces vascular mortality by ~17% and major vascular events by ~25% without increasing non-vasc…
DOI: 10.1186/1741-7015-3-6 -
Statin usage and all‐cause and disease‐specific mortality in a nationwide study
This nationwide study analyzes the association between statin use and all-cause and disease-specific mortality in Finland, finding that long-term statin use is linked to a reduction in coronary heart disease mortality.
DOI: 10.1002/pds.2255 -
The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.
This meta-analysis compares upfront lipid-lowering therapy combining statins with ezetimibe versus statin monotherapy, showing greater LDL-C reduction and improved cardiovascular outcomes with similar safety profiles across 11 studies comprising 106,358 participants.
DOI: 10.1093/eurheartj/ehae666.2873 -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
This systematic review evaluates the effects of statin therapy on cardiovascular outcomes and kidney function in adults with chronic kidney disease not on dialysis, finding that statins significantly reduce mortality and major cardiovascular events but have uncertain effects on …
DOI: 10.1590/1516-3180.20151336T2 -
A peri‐operative statin update for non‐cardiac surgery. Part II: Statin therapy for vascular surgery and peri‐operative statin trial design
This narrative review concludes that current retrospective evidence suggests peri-operative statin therapy may reduce mortality and myocardial infarction in non-cardiac vascular surgery, but confounding likely overestimates benefit, so recommendations support use in patients wit…
DOI: 10.1111/j.1365-2044.2007.05265.x -
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention
In a large unselected cohort of 1001 candidates for PCI, the study shows that full clopidogrel-induced platelet inhibition after a 600 mg loading dose is achieved by 2 hours, with no additional time-dependent improvement thereafter and no significant impact of concomitant statin…
DOI: 10.1161/01.cir.0000160869.75810.98 -
Statin Safety: A Systematic Review
This systematic review assesses the incidence and characteristics of adverse effects associated with statin use, revealing significant findings on rhabdomyolysis, myopathy, liver disease, and other potential side effects.
DOI: 10.1016/j.amjcard.2005.12.010 -
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug–drug interaction
This case study describes a 75-year-old man who developed atorvastatin-related rhabdomyolysis and acute renal failure, highlighting the role of genetic predisposition and drug-drug interactions in the adverse effects of statin therapy.
DOI: 10.1007/s11096-012-9717-0 -
The safety of statins in clinical practice
A comprehensive 2007 Lancet review assessing the safety of statins in clinical practice, detailing muscle and liver adverse effects, dose-related risks, drug interactions, and safety across diverse patient groups, and concluding that statins are generally well tolerated with cau…
DOI: 10.1016/S0140-6736(07)60716-8 -
Statin-Associated Myopathy
Statins are associated with skeletal muscle complaints including myositis, rhabdomyolysis, myalgia, weakness, and cramps; the FDA MEDWATCH database lists 3339 cases of statin-associated rhabdomyolysis from 1990 to 2002, with cerivastatin most commonly implicated, and risk is exa…
DOI: 10.1001/jama.289.13.1681 -
In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin‐induced adverse effects
Statins may unmask latent calcium homeostasis impairment in patients with myalgia and rhabdomyolysis, as indicated by abnormal in vitro contracture tests and slowed muscle pH recovery, with normal mitochondrial function.
DOI: 10.1002/art.22100 -
Review of Side-Effect Profile of Combination Ezetimibe and Statin Therapy in Randomized Clinical Trials
This systematic review assesses the side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials, finding no significant increase in adverse events compared to statin monotherapy across 18 trials involving 14,471 patients.
DOI: 10.1016/j.amjcard.2008.01.041 -
Takotsubo Cardiomyopathy with Involvement of Delayed-onset Rhabdomyolysis and Acute Kidney Injury after Rosuvastatin Treatment
This study presents a case of Takotsubo cardiomyopathy triggered by delayed-onset rhabdomyolysis following long-term rosuvastatin treatment, highlighting the need for awareness of this rare side effect in patients on statins.
DOI: 10.2169/internalmedicine.54.3239 -
Simvastatin‐Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two Patients
This study reports two cases of rhabdomyolysis in elderly patients following the coadministration of simvastatin with macrolide antibiotics, highlighting the potential for severe drug interactions and the need for careful management of statin therapy in vulnerable populations.
DOI: 10.1592/phco.27.4.603 -
Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction
This case report describes a 51-year-old woman who developed rhabdomyolysis and third-degree atrioventricular block, potentially due to an interaction between atorvastatin, esomeprazole, and clarithromycin.
DOI: 10.1345/aph.1c396